Skip to content
Study details
Enrolling now

Gabapentin & Ketamine Trial

Natalie Lockney
NCT IDNCT05156060ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

64

Study length

about 4.9 years

Ages

21+

Locations

1 site in TN

What this study is about

Researchers are testing the safety and best dose of gabapentin and ketamine to prevent or treat pain in people with locally advanced head and neck cancer who are receiving chemotherapy and radiation. The trial will last for about 18 months.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Gabapentin
  • 2.Take Ketamine

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

gabapentin (Modulates calcium channels; used for neuropathic pain and seizures), ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Count of participants with adverse events (Common Terminology Criteria for Adverse Events Criteria 4.0), Establish the maximum tolerated dose of ketamine in combination with gabapentin (per Common Terminology Criteria for Adverse Events Criteria 4.0)

Body systems

Oncology